College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board

Graadt van Roggenweg 500
3531 AH Utrecht
The Netherlands

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Histodine 10 mg/ml Solution for injection for cattle

Created: August 2019

MODULE 1

PRODUCT SUMMARY

EU Procedure number	NL/V/0211/001/DC
Name, strength and pharmaceutical form	Histodine 10 mg/ml Solution for injection for cattle
Applicant	Le Vet Beheer B.V. Wilgenweg 7 3421 TV Oudewater Netherlands
Active substance(s)	Chlorphenamine maleate
ATC Vetcode	QR06AB04
Target species	Cattle
Indication for use	For all conditions attributed to histamine release, for example, pharyngitis, laryngitis, tracheitis, bronchitis, bronchial spasm, urticaria, serum shock, anaphylaxis phenomena, laminitis and for the symptomatic treatment of inflammatory oedema.

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Veterinary Medicines Agencies website (http://www.HMA.eu).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Generic application in accordance with Article 13(1) of Directive 2001/82/EC as amended
Date of completion of the original decentralised procedure	29 March 2017
Date product first authorised in the Reference Member State (MRP only)	N/A
Concerned Member States for original procedure	BE, CY, CZ, EE, ES, FR, HU, IE, IS, IT, LT, LU, LV, PL, PT, RO, SK, UK

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.
It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.
The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.
The efficacy of the product was demonstrated according to the claims made in the SPC.
The overall risk/benefit analysis is in favour of granting a marketing authorisation.

Histodine is a generic product in accordance with Article 13(1). The reference product Neo-Antergan CM, authorized in Italy to Ceva Animla Health SpA. The initial application for Antergan CM was assessed before there was a requirement to have a public assessment report.

II. QUALITY ASPECTS

A. Qualitative and quantitative particulars

The product contains 10 mg/ml of the active substance chlorphenamine maleate and the excipients methyl parahydroxybenzoate, propyl parahydroxybenzoate, disodium phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate and water for injection.

The container/closure system consists of 100 ml and 250 ml vials composed of clear type II glass or polypropylene sealed with a bromobutyl coated stopper and an aluminium overseal and packaged in an outer carton.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is chlorphenamine maleate an established active substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.
The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

D. Control on intermediate products

Not applicable.

E. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site<s> have been provided demonstrating compliance with the specification.

F. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

The claim of 56 day stability after broaching is based on the demonstration of stability for batches broached and stored 56 days at 25°C.

G. Other Information

Shelf life of the veterinary medicinal product as packaged for sale: 2 years.
Shelf life after opening of the immediate packaging: 56 days.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of pharmaco-toxicological tests are not required.

The pharmaco-toxicological aspects of this product is/are identical to the reference product.

Warnings and precautions as listed on the product literature are the same or more extensive as those of the reference product and are adequate to ensure safety of the product to users / the environment / consumers.

User Safety

The applicant has provided a user safety assessment in compliance with the relevant guideline which resulted in the following warnings: Chlorphenamine can cause sedation. Precautions should be taken to avoid accidental self-injection with this drug. Preferably use a guarded needle until the moment of injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician. DO NOT DRIVE.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines. The environmental risk assessment can stop in Phase I and no Phase II assessment is required because the veterinary medicinal product will be used to treat a small number of animals in a flock or herd.

Withdrawal Periods

As this is a generic application according to Article 13(1), withdrawal periods are identical to the withdrawal periods of the reference product. Therefore, a withdrawal period of 1 day for meat in cattle and 12 hours for milk are justified.

IV. CLINICAL ASSESSMENT (EFFICACY)

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the Heads of Vetrinary Medicines Agencies website (www.HMA.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

Summary of change (Application number)	**Section updated in Module 3**	**Approval date**
Introduction of a new Pharmacovigilance system (Dechra Pharmaceuticals PLC) which has been assessed by the relevant national competent authority/EMA for another product of the same MAH. (NL/V/xxxx/WS/021)	N/A	12 July 2019